Idera Pharmaceuticals, Inc. Opens Enrollment For Phase 1/2 Clinical Trial Of IMO-8400 In Waldenstrom's Macroglobulinemia

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that enrollment is open for a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström’s macroglobulinemia, following acceptance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). The objectives of the trial are to evaluate the compound’s safety, tolerability, and potential clinical activity.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news